Royalty Pharma Acquires Royalty Interest in Nuvalent’s Neladalkib and Zidesamtinib for Up to $315 Million

Core Insights - Royalty Pharma has acquired a royalty interest in Nuvalent's neladalkib and zidesamtinib for up to $315 million [1][4] - Neladalkib and zidesamtinib are next-generation tyrosine kinase inhibitors (TKIs) targeting specific mutations in non-small cell lung cancer (NSCLC) [2] - Positive pivotal results for neladalkib have been reported, showing durable activity and a well-tolerated safety profile [3] Transaction Details - The acquisition includes a low-single digit royalty on worldwide net sales of both therapies, expected to last until approximately 2041 to 2042 [4] - The total investment for the royalty interest is capped at $315 million [4] Product Development Status - Neladalkib is in a Phase 3 study for TKI-naïve patients, while zidesamtinib is under FDA review with an action date of September 18, 2026 [3] - Analyst consensus projects sales of neladalkib to reach approximately $3.5 billion and zidesamtinib to reach approximately $1.9 billion by 2035 [3] Company Background - Royalty Pharma is the largest buyer of biopharmaceutical royalties and funds innovation across the biopharmaceutical industry [6] - The company has a diverse portfolio that includes royalties on over 35 commercial products and 20 development-stage candidates [6]